Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth

Glioma growth and progression are characterized by abundant development of blood vessels that are highly aberrant and poorly functional, with detrimental consequences for drug delivery efficacy. The mechanisms driving this vessel dysmorphia during tumor progression are poorly understood. Using longitudinal intravital imaging in a mouse glioma model, we identify that dynamic sprouting and functional morphogenesis of a highly branched vessel network characterize the initial tumor growth, dramatically changing to vessel expansion, leakage, and loss of branching complexity in the later stages. This vascular phenotype transition was accompanied by recruitment of predominantly pro‐inflammatory M1‐like macrophages in the early stages, followed by in situ repolarization to M2‐like macrophages, which produced VEGF‐A and relocate to perivascular areas. A similar enrichment and perivascular accumulation of M2 versus M1 macrophages correlated with vessel dilation and malignancy in human glioma samples of different WHO malignancy grade. Targeting macrophages using anti‐CSF1 treatment restored normal blood vessel patterning and function. Combination treatment with chemotherapy showed survival benefit, suggesting that targeting macrophages as the key driver of blood vessel dysmorphia in glioma progression presents opportunities to improve efficacy of chemotherapeutic agents. We propose that vessel dysfunction is not simply a general feature of tumor vessel formation, but rather an emergent property resulting from a dynamic and functional reorganization of the tumor stroma and its angiogenic influences.

[1]  S. Okada,et al.  IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation , 2010, Cell Death and Differentiation.

[2]  Holger Gerhardt,et al.  Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation. , 2008, Journal of theoretical biology.

[3]  I. Keklikoglou,et al.  Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. , 2015, Cancer research.

[4]  Na Zhang,et al.  Deletion of Vascular Endothelial Growth Factor in myeloid cells accelerates tumorigenesis , 2008, Nature.

[5]  F. Geissmann,et al.  Blood monocytes: development, heterogeneity, and relationship with dendritic cells. , 2009, Annual review of immunology.

[6]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[7]  L. Gleaves,et al.  A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis , 2011, The Journal of Immunology.

[8]  K. Alitalo,et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.

[9]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[10]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[11]  C. James,et al.  Immunocompetent murine models for the study of glioblastoma immunotherapy , 2014, Journal of Translational Medicine.

[12]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[13]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[14]  R. Kiss,et al.  Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy , 2017, Scientific Reports.

[15]  D. Gillespie,et al.  Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. , 2006, Journal of neuro-oncology.

[16]  D. McDonald,et al.  Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.

[17]  Stephen Mok,et al.  CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.

[18]  H. Gerhardt,et al.  Synchronization of endothelial Dll4-Notch dynamics switch blood vessels from branching to expansion , 2016, eLife.

[19]  E. Argandoña,et al.  Angiogenic Signalling Pathways Altered in Gliomas: Selection Mechanisms for More Aggressive Neoplastic Subpopulations with Invasive Phenotype , 2012, Journal of signal transduction.

[20]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[21]  J. Kuo,et al.  CSF1 Overexpression Promotes High-Grade Glioma Formation without Impacting the Polarization Status of Glioma-Associated Microglia and Macrophages. , 2016, Cancer research.

[22]  L. Ellis,et al.  Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. , 2004, Journal of the National Cancer Institute.

[23]  Stella E Tsirka,et al.  Microglia/macrophages promote glioma progression , 2011, Glia.

[24]  B. Faddegon,et al.  TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy , 2015, Cancer Immunology Research.

[25]  Sharmila Patel,et al.  Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. , 2009, Current topics in medicinal chemistry.

[26]  M. Mazzone,et al.  Altering the intratumoral localization of macrophages to inhibit cancer progression , 2014, Oncoimmunology.

[27]  L. Luo,et al.  A global double‐fluorescent Cre reporter mouse , 2007, Genesis.

[28]  L. Coussens,et al.  Myeloid Cells as Targets for Therapy in Solid Tumors. , 2015, Cancer journal.

[29]  Frank Bradke,et al.  Lifeact mice for studying F-actin dynamics , 2010, Nature Methods.

[30]  B. Faddegon,et al.  TH 2-Polarized CD 4 þ T Cells and Macrophages Limit Ef fi cacy of Radiotherapy , 2015 .

[31]  J. Julien,et al.  Increased glioma growth in mice depleted of macrophages. , 2007, Cancer research.

[32]  P. De Baetselier,et al.  Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. , 2010, Cancer research.

[33]  H. Lin,et al.  Regulation of Systemic Macrophage IL‐1 Gene Transcription: The Involvement of Tumor‐Derived Macrophage Growth Factor, CSF‐1 , 1989, Journal of leukocyte biology.

[34]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[35]  B. Tomczuk,et al.  JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia , 2009, Molecular Cancer Therapeutics.

[36]  G. Rougon,et al.  An orthotopic glioblastoma mouse model maintaining brain parenchymal physical constraints and suitable for intravital two-photon microscopy. , 2014, Journal of visualized experiments : JoVE.

[37]  Paul A. Bates,et al.  Tipping the Balance: Robustness of Tip Cell Selection, Migration and Fusion in Angiogenesis , 2009, PLoS Comput. Biol..

[38]  G. Christofori,et al.  Corrupt policemen: inflammatory cells promote tumor angiogenesis , 2009, Current opinion in oncology.

[39]  D. Gillespie,et al.  Inhibition of hypoxia inducible factor-1α (HIF-1α) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas , 2006, Journal of Neuro-Oncology.

[40]  L. Naldini,et al.  Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. , 2007, Trends in immunology.

[41]  T. Seyfried,et al.  Ganglioside distribution in murine neural tumors. , 1992, Molecular and chemical neuropathology.

[42]  P. Chambon,et al.  Efficient, inducible Cre‐recombinase activation in vascular endothelium , 2008, Genesis.

[43]  M. Lampugnani,et al.  Differential adhesion drives angiogenesis , 2014, Nature Cell Biology.

[44]  D. Hume,et al.  Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. , 2012, Blood.

[45]  D. Reardon,et al.  Molecularly targeted therapy for malignant glioma , 2007, Cancer.

[46]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[47]  H. Hamada,et al.  Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy , 2006, Cancer science.

[48]  Dmitriy M Chudakov,et al.  Conversion of red fluorescent protein into a bright blue probe. , 2008, Chemistry & biology.

[49]  Yuquan Wei,et al.  Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.

[50]  J. Hamilton,et al.  The Promotion of Breast Cancer Metastasis Caused by Inhibition of CSF-1R/CSF-1 Signaling Is Blocked by Targeting the G-CSF Receptor , 2014, Cancer Immunology Research.

[51]  A. Sica,et al.  Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs) , 2012, Cancer Microenvironment.

[52]  Michael C. Schmid,et al.  Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation , 2010, Journal of oncology.

[53]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[54]  L. Boon,et al.  DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. , 2009, Neuro-oncology.

[55]  M. Dolan,et al.  Activity of temozolomide in the treatment of central nervous system tumor xenografts. , 1995, Cancer research.

[56]  H. Vogel,et al.  Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. , 2010, The Journal of clinical investigation.

[57]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[58]  M R Grever,et al.  Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. , 1994, Cancer research.

[59]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[60]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[61]  R. Adams,et al.  DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. , 2009, Blood.

[62]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[63]  A. Philippides,et al.  The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis , 2014, Nature Cell Biology.

[64]  R. Head,et al.  Transcriptional profiling and pathway analysis of CSF-1 and IL-34 effects on human monocyte differentiation. , 2013, Cytokine.

[65]  Holger Gerhardt,et al.  Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. , 2002, Genes & development.

[66]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[67]  Clare L. Bennett,et al.  DC ablation in mice: promises, pitfalls, and challenges. , 2007, Trends in immunology.